Literature DB >> 1430218

Distribution of apolipoprotein(a) in the plasma from patients with lipoprotein lipase deficiency and with type III hyperlipoproteinemia. No evidence for a triglyceride-rich precursor of lipoprotein(a).

C Sandholzer1, G Feussner, J Brunzell, G Utermann.   

Abstract

Lipoprotein(a) consists of a low-density lipoprotein containing apolipoprotein (apo) B-100 and of the genetically polymorphic apo(a). It is not known where and how lipoprotein(a) is assembled and whether there exists a precursor for lipoprotein(a). We have determined the phenotype, concentration, and distribution of apo(a) in plasma from patients with lipoprotein lipase (LPL) deficiency (type I hyperlipoproteinemia, n = 14), in apo E 2/2 homozygotes with type III hyperlipoproteinemia (n = 12) and in controls (n = 16). In the two genetic conditions, there is grossly impaired catabolic conversion of apo B-100-containing precursor lipoproteins to low-density lipoproteins. Considering apo(a) type, the plasma concentration of apo(a) was normal in type III patients but significantly reduced in LPL deficiency. Despite the defects in the catabolism of other apo B-containing lipoproteins, the distribution of apo(a) was only moderately affected in both metabolic disorders, with 66.7% (type I) and 74.7% (type III) being present as the characteristic lipoprotein(a) in the density range of 1.05-1.125 g/ml (controls 81.6%). The remainder was distributed between the triglyceride-rich lipoproteins (type I 12.4%, type III 8.5%, controls 4.7%) and the lipid-poor bottom fraction (type I 19.3%, type III 15.3%, controls 12.6%). In all conditions most apo(a) (57-88%) dissociated from the triglyceride-rich lipoproteins upon recentrifugation and was recovered as lipoprotein(a). These data suggest that lipoprotein(a) is not generated from a triglyceride-rich precursor. Lipoprotein(a) may be secreted directly into plasma or may be formed by preferential binding of secreted apo(a) to existing low-density lipoprotein.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1430218      PMCID: PMC443258          DOI: 10.1172/JCI116074

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  40 in total

1.  Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis.

Authors:  H G Kraft; H J Menzel; F Hoppichler; W Vogel; G Utermann
Journal:  J Clin Invest       Date:  1989-01       Impact factor: 14.808

2.  Separation of plasma lipoproteins by density-gradient ultracentrifugation.

Authors:  T G Redgrave; D C Roberts; C E West
Journal:  Anal Biochem       Date:  1975-05-12       Impact factor: 3.365

3.  Relationship between apo[a] isoforms and Lp[a] density in subjects with different apo[a] phenotype: a study before and after a fatty meal.

Authors:  D Pfaffinger; J Schuelke; C Kim; G M Fless; A M Scanu
Journal:  J Lipid Res       Date:  1991-04       Impact factor: 5.922

4.  Expressed hypervariable polymorphism of apolipoprotein (a).

Authors:  M I Kamboh; R E Ferrell; B A Kottke
Journal:  Am J Hum Genet       Date:  1991-11       Impact factor: 11.025

5.  Polymorphic forms of human apolipoprotein[a]: inheritance and relationship of their molecular weights to plasma levels of lipoprotein[a].

Authors:  J W Gaubatz; K I Ghanem; J Guevara; M L Nava; W Patsch; J D Morrisett
Journal:  J Lipid Res       Date:  1990-04       Impact factor: 5.922

6.  Lipoprotein(a) binding to other apolipoprotein B containing lipoproteins.

Authors:  V N Trieu; W J McConathy
Journal:  Biochemistry       Date:  1990-06-26       Impact factor: 3.162

Review 7.  The mysteries of lipoprotein(a).

Authors:  G Utermann
Journal:  Science       Date:  1989-11-17       Impact factor: 47.728

8.  Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups.

Authors:  C Sandholzer; D M Hallman; N Saha; G Sigurdsson; C Lackner; A Császár; E Boerwinkle; G Utermann
Journal:  Hum Genet       Date:  1991-04       Impact factor: 4.132

9.  Lipoprotein metabolism during acute inhibition of hepatic triglyceride lipase in the cynomolgus monkey.

Authors:  I J Goldberg; N A Le; J R Paterniti; H N Ginsberg; F T Lindgren; W V Brown
Journal:  J Clin Invest       Date:  1982-12       Impact factor: 14.808

10.  Fat feeding in humans induces lipoproteins of density less than 1.006 that are enriched in apolipoprotein [a] and that cause lipid accumulation in macrophages.

Authors:  T P Bersot; T L Innerarity; R E Pitas; S C Rall; K H Weisgraber; R W Mahley
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

View more
  9 in total

Review 1.  Structure, function, and genetics of lipoprotein (a).

Authors:  Konrad Schmidt; Asma Noureen; Florian Kronenberg; Gerd Utermann
Journal:  J Lipid Res       Date:  2016-04-13       Impact factor: 5.922

2.  Apolipoprotein B-100-containing lipoprotein metabolism in subjects with lipoprotein lipase gene mutations.

Authors:  Esther M M Ooi; Betsy S Russell; Eric Olson; Sam Z Sun; Margaret R Diffenderfer; Alice H Lichtenstein; Leonard Keilson; P Hugh R Barrett; Ernst J Schaefer; Dennis L Sprecher
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-11-17       Impact factor: 8.311

3.  The apolipoprotein B3304-3317 peptide as an inhibitor of the lipoprotein (a):apolipoprotein B-containing lipoprotein interaction.

Authors:  V N Trieu; U Olsson; W J McConathy
Journal:  Biochem J       Date:  1995-04-01       Impact factor: 3.857

4.  Apolipoprotein E phenotype and lipoprotein(a) in familial hypercholesterolaemia: implication for lipoprotein(a) metabolism.

Authors:  G Lindahl; F Mailly; S Humphries; M Seed
Journal:  Clin Investig       Date:  1994-08

Review 5.  Lipoprotein(a): new insights into an atherogenic lipoprotein.

Authors:  W Bartens; C Wanner
Journal:  Clin Investig       Date:  1994-08

6.  Relation of cardiovascular risk factors to atherosclerosis in type III hyperlipoproteinemia.

Authors:  G Feussner; A Wagner; R Ziegler
Journal:  Hum Genet       Date:  1993-09       Impact factor: 4.132

7.  Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a).

Authors:  M J Callow; J Verstuyft; R Tangirala; W Palinski; E M Rubin
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

8.  Lipoprotein(a): an independent risk factor for ischemic heart disease that is dependent on triglycerides in subjects with type 2 diabetes mellitus.

Authors:  Ali Albahrani; Mohammed Alkindi; Eileen Marks; Said Alyahyaee; Alan Shenkin
Journal:  Lipids Health Dis       Date:  2007-10-02       Impact factor: 3.876

Review 9.  Apolipoprotein(a) is the Product of a Pseudogene: Implications for the Pathophysiology of Lipoprotein(a).

Authors:  Gregory D Sloop; Gheorghe Pop; Joseph J Weidman; John A St Cyr
Journal:  Cureus       Date:  2018-05-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.